Filana Therapeutics to Participate in the 2026 Maxim Growth Summit

AUSTIN, Texas, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the Company’s management team will participate in the 2026 Maxim Growth Summit being held October 12-14, 2026 in New York. 2026 Maxim Growth Summit Conference Details: Format: One-on-one meetings Date: October 12–14, 2026 Location: The Hard Rock Hotel NYC For more information and a complete agenda, please visit www.maximgrp.com/2026-growth-summit. About Filana Therapeutics, Inc. Filana Therapeutics, Inc. (NASDAQ: FLNA), is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. For more information, please visit: https://www.FilanaTx.com For More Information Contact: Investors Mike Moyer mmoyer@lifesciadvisors.com Company Eric Schoen, Chief Financial Officer (512) 501-2450 ESchoen@FilanaTx.com IR@FilanaTx.com